Edgestream Partners L.P. Boosts Stake in Exelixis, Inc. $EXEL

Posted by on Jul 31st, 2026

Edgestream Partners L.P. raised its stake in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 21.1% during the first quarter, Holdings Channel.com reports. The institutional investor owned 174,455 shares of the biotechnology company’s stock after buying an additional 30,356 shares during the period. Edgestream Partners L.P.’s holdings in Exelixis were worth $7,482,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of EXEL. Motiv8 Investments LLC purchased a new position in shares of Exelixis during the fourth quarter valued at approximately $26,000. Cassaday & Co Wealth Management LLC acquired a new stake in Exelixis during the first quarter worth approximately $27,000. Acumen Wealth Advisors LLC purchased a new stake in Exelixis in the 4th quarter worth approximately $29,000. Activest Wealth Management purchased a new stake in Exelixis in the 4th quarter worth approximately $32,000. Finally, Northwestern Mutual Wealth Management Co. raised its holdings in Exelixis by 1,380.4% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 829 shares of the biotechnology company’s stock valued at $34,000 after acquiring an additional 773 shares during the last quarter. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Dana Aftab sold 43,451 shares of Exelixis stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $50.35, for a total transaction of $2,187,757.85. Following the sale, the executive vice president owned 594,741 shares of the company’s stock, valued at $29,945,209.35. The trade was a 6.81% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Christopher J. Senner sold 34,901 shares of the business’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $50.00, for a total transaction of $1,745,050.00. Following the completion of the transaction, the chief financial officer owned 952,317 shares in the company, valued at $47,615,850. This represents a 3.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 219,170 shares of company stock valued at $10,620,641. Corporate insiders own 2.60% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. UBS Group reissued a “buy” rating on shares of Exelixis in a research note on Thursday, July 2nd. Truist Financial lifted their price objective on Exelixis from $54.00 to $56.00 and gave the company a “hold” rating in a research report on Tuesday, July 7th. TD Cowen upped their target price on Exelixis from $51.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. HC Wainwright reiterated a “buy” rating and set a $56.00 target price on shares of Exelixis in a research report on Thursday, July 2nd. Finally, Morgan Stanley raised their price target on Exelixis from $50.00 to $53.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 23rd. Eight analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $49.29.

View Our Latest Analysis on EXEL

Exelixis Stock Up 1.2%

Exelixis stock opened at $55.97 on Friday. The firm has a fifty day moving average of $53.67 and a 200-day moving average of $47.54. Exelixis, Inc. has a 52-week low of $33.76 and a 52-week high of $57.57. The firm has a market capitalization of $14.07 billion, a P/E ratio of 18.59, a PEG ratio of 1.60 and a beta of 0.42.

Exelixis (NASDAQ:EXEL – Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.75 by $0.12. The company had revenue of $610.81 million for the quarter, compared to analyst estimates of $607.51 million. Exelixis had a return on equity of 39.89% and a net margin of 35.08%.The firm’s revenue was up 10.0% compared to the same quarter last year. During the same period last year, the company posted $0.55 earnings per share. On average, research analysts expect that Exelixis, Inc. will post 3.15 EPS for the current fiscal year.

Exelixis Company Profile

(Free Report)

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.

Featured Articles

Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL – Free Report).

Institutional Ownership by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.